However, a recent study has demonstrated that improved survival of glioblastoma patients benefiting from metronomic temozolomide-based therapies and showing an EGFR overexpression is associated with activated EGFR/PI3K/Akt pathway independently of the presence of EGFRvIII [34]. Here, EGFR is linked to glioblastoma.